Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
On March 11, the Securities and Exchange Commission (SEC) and Commodity Futures Trading Commission (CFTC) signed a memorandum of understanding (MOU) that both agencies describe as “historic.” The MOU is intended to reset the relationship between the agencies by reducing turf battles, avoiding duplicative regulation, and providing clearer, technology-neutral oversight — particularly in markets where securities and derivatives regimes overlap, including crypto. While it does not change either agency’s statutory authority, it creates a formal framework for coordination that will materially affect how policy, examinations, and enforcement play out in practice.
Background
The SEC and CFTC share oversight of increasingly convergent markets such as trading venues, clearinghouses, data repositories, pooled vehicles, intermediaries, and products that sit at the intersection of securities and derivatives. For years, market participants, especially dual registrants, have faced duplicative registrations, overlapping rules, and parallel exams or investigations. The agencies expressly acknowledge that this fragmentation has at times “stifled innovation and pushed market participants to other jurisdictions.”
To combat these challenges, the new MOU replaces the 2018 coordination MOU and builds on earlier efforts to forge a partnership between the agencies (including the 2004 security futures MOU). The new MOU emphasizes “minimum effective dose” regulation that supports lawful innovation, fair notice (as opposed to “regulation by enforcement), and a renewed commitment to collaboration. It is accompanied by a Joint Harmonization Initiative co-led by Robert Teply of the SEC and Meghan Tente of the CFTC, which will carry the coordination into concrete workstreams.
Key Points
Our Take
For firms active in both SEC and CFTC markets, this MOU is a signal that overlapping oversight will become more coordinated, more data-driven, and less duplicative. Dual registrants should anticipate closer alignment in exams and enforcement and fewer instances of inconsistent messaging between the agencies. At the same time, the emphasis on “minimum effective dose” regulation, fair notice, and fit-for-purpose frameworks opens the door for constructive engagement on streamlining requirements and designing compliant, innovative products and platforms, particularly in crypto and other technology-heavy areas.
Resources
This just in
Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
Speaking Engagements
Performance on Trial: The Construction Manager’s Standard of Care Examined from All Angles
December 2, 2026 | 4:15 PM – 5:30 PM ET
The Hyatt Regency Huntington Beach
Huntington Beach, CA
Speaking Engagements
ACI’s 31st Annual Conference on Drug & Medical Device Litigation – 2026
December 2 – 3, 2026
New York Marriott Marquis
1535 Broadway, New York, NY 10036
Speaking Engagements
Entering the Defense Market: USA, Canada, Ukraine, UK, Germany, Poland
November 19, 2026 | 3:00 PM – 5:00 PM CT
Virtual